Recently, combinations of STING with other cancer drugs have become an appealing strategy; yet a clinical trial (NCT 03172936) combining ADU-S100 with anti-programmed death-1 (PD-1) also yielded disappointing responses 8. Here, STING1 is linked to cancer.